UCB Sa operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Lonza Group AG
sales of 5.54 billion Swiss Francs [US$5.61 billion]
of which 56%
(251.73 billion Russian Rubles [US$3.96 billion]
of which 72%
was Distribution), and
based in Spain
(4.49 billion Euro [US$4.96 billion]
of which 78%
UCB Sa reported sales of 4.63 billion Euro (US$5.12 billion)
December of 2018.
increase of 2.3%
versus 2017, when the company's sales were 4.53 billion Euro.
This was the fourth straight year of sales growth at UCB Sa.